Concepedia

Author

Jana Prausová

University Hospital in Motol

Also Known As

J Prausová, J. PRAUSOVA, J. PRAUSOVÁ, J. Prausova, J. Prausová, Jana Katolicka, Jana Prausova, Jana Prausovà, Jana Prausová, Ladislav Dusek

93

Publications

7.1K

Citations

25

H-Index

35

Concepts

All Affiliations

University Hospital in MotolMasaryk Memorial Cancer InstituteCharles UniversityKU LeuvenUnified Szent István and Szent László Hospital
JP

About

Jana Prausová is an author at University Hospital in Motol specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

18

2.6K

2

Health Sciences

4

4

655

3

Immunology

3

3

118

4

Emergency Medicine

1

1

22

5

Gastroenterology

1

1

17

Jana Prausová

×

31

Publications

6.9K

Citations

24

H-Index

YearCitations

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem, Josep Tabernero, Radek Lakomý,

Journal of Clinical Oncology

2012

1.4K

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

David H. Henry, Luís Costa, François Goldwasser,

Journal of Clinical Oncology

2011

1.3K

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto Sobrero, Joan Maurel, Louis Fehrenbacher,

Journal of Clinical Oncology

2008

945

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn,

The Lancet Oncology

2015

938

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen,

The Lancet Oncology

2017

578

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Josep Tabernero, Eric Van Cutsem, Radek Lakomý,

European Journal of Cancer

2013

236

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra,

The Lancet Oncology

2024

174

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

Matthias Löhr, Stephan Haas, Wolf O. Bechstein,

Annals of Oncology

2011

105

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André,

Annals of Oncology

2013

101

Page 1